ACM
CBAY

AlphaCrest Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

AlphaCrest Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30,100
Closed -$154K – 1419
2019
Q3 		$154K Buy
30,100
+4,300
+17% +$26K 0.01% 1231
2019
Q2 		$185K Buy
+25,800
New +$292K 0.02% 977

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AlphaCrest Capital Management's CBAY Position: Q4 2019 in Review

AlphaCrest Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 30,100 shares — an estimated $154K sold.

AlphaCrest Capital Management first reported a position in CBAY in Q2 2019 and held it in 2 quarters. The position peaked at $185K in Q2 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

  • AlphaCrest Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
  • AlphaCrest Capital Management sold 30,100 Cymabay Therapeutics shares in Q4 2019, an estimated $154K.
  • AlphaCrest Capital Management first reported a position in Cymabay Therapeutics in Q2 2019 and held it in 2 quarters.
  • AlphaCrest Capital Management's Cymabay Therapeutics position peaked at $185K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on AlphaCrest Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.